<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663399</url>
  </required_header>
  <id_info>
    <org_study_id>BMR_2020_32</org_study_id>
    <nct_id>NCT04663399</nct_id>
  </id_info>
  <brief_title>IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)</brief_title>
  <acronym>IMPRESS</acronym>
  <official_title>IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles&#xD;
      during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and&#xD;
      to study the possible impact of these profiles on the functional prognosis at 3 months of AIC&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immuno-inflammatory and thrombo-inflammatory profiles in patients suffering from AIC and treated with mechanical Thrombectomie.</measure>
    <time_frame>21 months</time_frame>
    <description>Blood plasma collected from patients at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment will be used to discover and validate panels of inflammatory biomarkers that are predictive of therapeutic response. The biomarkers will be measured using a multiplex preconfigured panels for inflammatory biomarkers.</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Thrombectomy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective patient</intervention_name>
    <description>The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for a mechanical thrombectomy as part of an AIC will be able to&#xD;
        participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting an acute ischemic stroke for which treatment by mechanical thrombectomy is&#xD;
             indicated according to European and North American recommendations (associated or not&#xD;
             with intravenous thrombolysis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracranial haemorrhage associated with acute ischemic stroke on initial imaging&#xD;
&#xD;
          -  Contraindication or non-indication to a mechanic thrombectomy&#xD;
&#xD;
          -  Immunosuppressive treatment or corticosteroid therapy on admission of the patient&#xD;
&#xD;
          -  Pre-existing neurological disability limiting the neurological assessment to 3 months&#xD;
             (mRS&gt;2 on admission)&#xD;
&#xD;
          -  Dementia known and diagnosed pre-existing at acute ischemic stroke&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Maier</last_name>
    <phone>0148036556</phone>
    <email>bmaier@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Yavchitz</last_name>
    <phone>0148036556</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

